Hatakeyama Takuya, Pappas Peter J, Hobson Robert W, Boric Mauricio P, Sessa William C, Durán Walter N
Program in Vascular Biology, Department of Pharmacology & Physiology, University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School, Newark, NJ 07101-1709, USA.
J Physiol. 2006 Jul 1;574(Pt 1):275-81. doi: 10.1113/jphysiol.2006.108175. Epub 2006 May 4.
Nitric oxide (NO) is an important regulator of blood flow, but its role in permeability is still challenged. We tested in vivo the hypotheses that: (a) endothelial nitric oxide synthase (eNOS) is not essential for regulation of baseline permeability; (b) eNOS is essential for hyperpermeability responses in inflammation; and (c) molecular inhibition of eNOS with caveolin-1 scaffolding domain (AP-Cav) reduces eNOS-regulated hyperpermeability. We used eNOS-deficient (eNOS-/-) mice and their wild-type control as experimental animals, platelet-activating factor (PAF) at 10(-7) m as the test pro-inflammatory agent, and integrated optical intensity (IOI) as an index of microvascular permeability. PAF increased permeability in wild-type cremaster muscle from a baseline of 2.4 +/- 2.2 to a peak net value of 84.4 +/- 2.7 units, while the corresponding values in cremaster muscle of eNOS-/- mice were 1.0 +/- 0.3 and 15.6 +/- 7.7 units (P < 0.05). Similarly, PAF increased IOI in the mesentery of wild-type mice but much less in the mesentery of eNOS-/- mice. PAF increased IOI to comparable values in the mesenteries of wild-type mice and those lacking the gene for inducible NOS (iNOS). Administration of AP-Cav blocked the microvascular hyperpermeability responses to 10(-7) m PAF. We conclude that: (1) baseline permeability does not depend on eNOS; (2) eNOS and NO are integral elements of the signalling pathway for the hyperpermeability response to PAF; (3) iNOS does not affect either baseline permeability or hyperpermeability responses to PAF; and (4) caveolin-1 inhibits eNOS regulation of microvascular permeability in vivo. Our results establish eNOS as an important regulator of microvascular permeability in inflammation.
一氧化氮(NO)是血流的重要调节因子,但其在通透性方面的作用仍存在争议。我们在体内测试了以下假设:(a)内皮型一氧化氮合酶(eNOS)对于调节基线通透性并非必不可少;(b)eNOS对于炎症中的高通透性反应至关重要;(c)用小窝蛋白-1支架结构域(AP-Cav)对eNOS进行分子抑制可降低eNOS调节的高通透性。我们使用eNOS基因缺陷(eNOS-/-)小鼠及其野生型对照作为实验动物,以10^(-7) m的血小板活化因子(PAF)作为测试促炎剂,并将积分光强度(IOI)作为微血管通透性的指标。PAF使野生型提睾肌的通透性从基线的2.4±2.2增加到峰值净值84.4±2.7单位,而eNOS-/-小鼠提睾肌的相应值分别为1.0±0.3和15.6±7.7单位(P<0.05)。同样,PAF增加了野生型小鼠肠系膜中的IOI,但在eNOS-/-小鼠的肠系膜中增加较少。PAF使野生型小鼠和缺乏诱导型NOS(iNOS)基因的小鼠肠系膜中的IOI增加到相当的值。给予AP-Cav可阻断对10^(-7) m PAF的微血管高通透性反应。我们得出以下结论:(1)基线通透性不依赖于eNOS;(2)eNOS和NO是对PAF高通透性反应信号通路的组成部分;(3)iNOS既不影响基线通透性也不影响对PAF的高通透性反应;(4)小窝蛋白-1在体内抑制eNOS对微血管通透性的调节。我们的结果确立了eNOS作为炎症中微血管通透性的重要调节因子。